Wegovy is the brand name of semaglutide, a GLP-1 receptor agonist used with reduced-calorie diet and increased physical activity for chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease and obesity/overweight, and treatment of noncirrhotic MASH with moderate-to-advanced fibrosis under accelerated approval. U.S. initial approval in this label is 2017.
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.
The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
The life sciences industry expects strong growth in 2026 driven by AI adoption and GLP-1 drug innovations, but faces headwinds from tariffs, FDA changes, and rising shareholder activism. Over 320 public activist campaigns have targeted life sciences companies since 2020, with 75-80% of biotech and pharma targets being pre-revenue firms.
Delaware's state employee health plan may raise GLP-1 copays from $32 to $120 per month or eliminate weight-loss drug coverage entirely, as costs are projected to reach $211 million by 2029. A decision is expected February 23, 2027.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07090343 |
Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement |
NOT_YET_RECRUITING | PHASE3 |
| NCT07036172 |
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients |
RECRUITING | PHASE3 |
| NCT06830343 |
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity |
RECRUITING | PHASE1 |
